anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The deletion of chromosome 17p (del(17p)) is considered a crucial prognostic factor at the time of diagnosis in patients with multiple myeloma (MM). However, the impact of del(17p) on survival at different clonal sizes at relapse, as well as the patterns of clonal evolution between diagnosis and relapse and their prognostic value, has not been well described. To address these issues, we analyzed the interphase fluorescence in situ hybridization (iFISH) results of 995 newly diagnosed MM (NDMM) patients and 293 patients with MM at their first relapse. Among these patients, 197 had paired iFISH data at diagnosis and first relapse. Our analysis of paired iFISH revealed that a minor clone of del(17p) at relapse but not at diagnosis was associated with poor prognosis in MM (hazard ratio for median overall survival 1.64 vs. 1.44). Fifty-six and 12 patients developed one or more new cytogenetic abnormalities at relapse, mainly del(17p) and gain/amp(1q), respectively. We classified the patients into six groups based on the change patterns in the clonal size of del(17p) between the two time points. Patients who did not have del(17p) during follow-up showed the best outcomes, whereas those who acquired del(17p) during their disease course, experienced compromised survival (median overall survival: 61.3 vs. 49.4 months; hazard ratio =1.64; 95% confidence interval: 1.06-2.56; P<0.05). In conclusion, our data confirmed the adverse impact of a minor clone of del(17p) at relapse and highlighted the importance of designing optimal therapeutic strategies to eliminate high-risk cytogenetic abnormalities (clinicaltrials gov. identifier: NCT04645199).
The injectable solns are obtd. by adding, to an isotonic or double isotonic concn. of the extract in distilled water, 0.5% phenol as preservative, adjusting the pH to 7.2-7.8 with N/10 acetic acid, introducing the soln. into flasks or bottles, and sterilising it at 75-85 degrees C for 1-3 hrs. each day on 3 consecutive days. The solns. are useful in the treatment of rheumatism, paradontosis, myalgias, neuropathies, etc. Suitable pelogenic extracts are obtd. from Amara mud and Tekirghiol. The biostimulant substances in the mud are not inactivated by the process.
Group of participants with a main dignosis os social anxiety disorder not subjected to any psychological intervention within the current trial. Assessed at time 0, then at time 1 ten to twelve weeks after time 1, then again at time 3 twelve weeks later, and then again at time 4 another twelve weeks later (i.e., 24 weeks after time 1).
Ten subjects will be randomly assigned at a 4: 1 ratio to receive either single dose of 20 μg PA9159 or placebo. There will be a one week follow-up period to review all available clinical and laboratory safety data before escalating to next dosing level.
Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients has bacteraemia.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of UBRELVY was evaluated in 3,624 subjects who received at least one dose of UBRELVY. In two randomized, double-blind, placebo-controlled, Phase 3 trials in adult patients with migraine (Studies 1 and 2), a total of 1,439 patients received UBRELVY 50 mg or 100 mg [see Clinical Studies (14)]. Of the UBRELVY-treated patients in these 2 studies, approximately 89% were female, 82% were White, 15% were Black, and 17% were of Hispanic or Latino ethnicity. The mean age at study entry was 41 years (range of 18-75 years). 

Long-term safety was assessed in 813 patients, dosing intermittently for up to 1 year in an open-label extension study. Patients were permitted to treat up to 8 migraines per month with UBRELVY. Of these 813 patients, 421 patients were exposed to 50 mg or 100 mg for at least 6 months, and 364 patients were exposed to these doses for at least one year, all of whom treated at least two migraine attacks per month, on average. In that study, 2.5% of patients were withdrawn from UBRELVY because of an adverse reaction. The most common adverse reaction resulting in discontinuation in the long-term safety study was nausea. 

Adverse reactions in Studies 1 and 2 are shown in Table 2. 

*Somnolence includes the adverse reaction-related terms sedation and fatigue.
Patients receive talazoparib PO daily on days 1-21 and gemtuzumab ozogamicin IV over 2 hours on days 1, 4, and 7 or day 1 for patients who CR/CRi after cycles 1 or 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Systemic effects such as hypercorticism and adrenal suppression may occur with use corticosteroids, including UCERIS. Monitor patients for signs and symptoms of hypercorticism and adrenal axis suppression during treatment with UCERIS.

Patients with moderate to severe liver disease should be monitored for increased signs and/or symptoms of hypercorticism. Discontinuing the use of UCERIS tablets should be considered in these patients [see Use in Specific Populations (8.6)].

Glucocorticosteroids, including UCERIS, can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In situations where patients are subject to surgery or other stress situations, supplementation with a systemic glucocorticosteroid is recommended.
OBJECTIVES: I. Determine the safety and toxicity profile, specifically cardiac toxicity, of trastuzumab (Herceptin) following high dose chemotherapy and autologous peripheral blood stem cell transplantation in women with metastatic breast cancer. II. Determine the time to disease progression and disease free survival in these patients when treated with this regimen. III. Determine the impact of trastuzumab (Herceptin) on minimal residual disease after autologous peripheral blood stem cell transplantation as evidenced by serial immunocytochemical analysis of bone marrow. IV. Determine the relationship between posttransplant reconstitution of antibody dependent cellular toxicity and the efficacy of trastuzumab (Herceptin) in these patients.

OUTLINE: This is a multicenter study. Patients undergo stem cell mobilization with growth factors alone (filgrastim (G-CSF) and/or sargramostim (GM-CSF)) or chemotherapy followed by growth factors (depending on center). Peripheral blood stem cells (PBSC) are then collected by leukapheresis. Patients then receive high dose chemotherapy consisting of cyclophosphamide IV over 1 hour and cisplatin IV over 72 hours on days -6 to -4 and carmustine IV on day -3 or cyclophosphamide IV, thiotepa IV, and carboplatin IV over 96 hours on days -7 to -4 (depending on center). PBSC are reinfused on day 0. Patients then receive trastuzumab IV over 30-90 minutes weekly for 1 year or until disease progression beginning 5-8 weeks after PBSC reinfusion.

PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.
Striae distensae (SD) are visible linear scars developing in areas of dermal damage. Insulin is a peptide hormone that can potentially help restore the integrity of damaged skin and promote the reformation of granulation tissue. Hyaluronic Acid is commonly used in aesthetic medicine. To evaluate the clinical response and efficacy of microneedling and topical insulin against microneedling and topical hyaluronic acid in treating stretch marks. The study was conducted on 30 patients suffering from striae distensae in the abdomen. The patients were treated by microneedling followed by hyaluronic acid on the right side. The second group was treated by microneedling followed by topical insulin on the left side of the abdomen. At the end of the study the improvement with hyaluronic acid was 23.3% of patients with excellent improvement and 30.0% of patients with marked improvement. The improvement with topical insulin was 30.0% of patients with excellent improvement and 20.0% of patients with marked improvement. Microneedling followed by hyaluronic acid or topical insulin can be an effective and safe therapeutic option for the treatment of Stretch marks with no significant side effects.
Cohort 1A will consist of both a single ascending dose (SAD) part and a multiple ascending dose (MAD). BMN 351 will be administered once every 2 weeks during the SAD portion of the study for up to 8 weeks and once weekly during the MAD portion for up to 56 weeks.
Oxycodone hydrochloride tablets have been evaluated in open label clinical trials in patients with cancer and nonmalignant pain. Oxycodone hydrochloride tablets are associated with adverse experiences similar to those seen with other opioids.

Serious adverse reactions that may be associated with oxycodone hydrochloride tablets therapy in clinical use are those observed with other opioid analgesics and include: respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension, and/or shock (see OVERDOSAGE, WARNINGS).

The less severe adverse events seen on initiation of therapy with oxycodone hydrochloride tablets are also typical opioid side effects. These events are dose dependent, and their frequency depends on the clinical setting, the patient's level of opioid tolerance, and host factors specific to the individual. They should be expected and managed as a part of opioid analgesia. The most frequent of these include nausea, constipation, vomiting, headache, and pruritus.

In many cases the frequency of adverse events during initiation of opioid therapy may be minimized by careful individualization of starting dosage, slow titration and the avoidance of large rapid swings in plasma concentration of the opioid. Many of these adverse events will abate as therapy is continued and some degree of tolerance is developed, but others may be expected to remain throughout therapy.

In all patients for whom dosing information was available (n=191) from the open-label and double-blind studies involving oxycodone hydrochloride tablets, the following adverse events were recorded in patients treated with oxycodone hydrochloride tablets with an incidence ≥ 3%. In descending order of frequency they were: nausea, constipation, vomiting, headache, pruritus, insomnia, dizziness, asthenia, and somnolence.

The following adverse experiences occurred in less than 3% of patients involved in clinical trials with oxycodone:
Following intravenous injection, radioiodinated serum albumin is uniformly distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly. Labeled albumin also can be detected in the lymph and in certain body tissues within 10 minutes after injection, but maximum distribution of radioactivity throughout the extravascular space does not occur until two to four days after administration. The time at which extravascular activity is maximal has been designated as the "equilibrium time." When this point has been reached, the radioactivity remaining in the intravascular and extravascular spaces decreases slowly and exponentially in parallel fashion.

The administered radioactivity is eliminated almost entirely in the urine, only about 2 percent of the total dose ultimately appearing in the feces. The biologic half-life of labeled albumin is dependent upon a number of factors, and published studies have varied considerably in their reporting of this figure. It has ranged, in the literature, from below 10 days to over 20 days. One important factor affecting the biologic half-life is the initial rate of excretion, and this depends in part on the quality of the labeled albumin. With Jeanatope 1-125 the biologic half-life in normal individuals has been reported to be approximately 14 days.
INTRODUCTION: Haemodialysis is the most common treatment option for patients with life-sustaining end-stage kidney disease (ESKD). In recent years, haemodiafiltration or haemofiltration has been widely used in patients with ESKD, and there are still conflicting findings as to whether both are superior to traditional haemodialysis. This systematic review and meta-analysis were designed to determine whether haemodiafiltration or haemofiltration is more effective than haemodialysis in reducing all-cause mortality risk in patients with ESKD.
METHODS AND ANALYSIS: We will perform a systematic PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library and Scopus search, including studies published before September 2023. Randomised controlled trials will be included exploring the effects of haemodiafiltration or haemofiltration compared with haemodialysis on prognosis in patients with ESKD. Outcomes of interest include all-cause mortality, cardiovascular events, dialysis adequacy and adverse effects. The Cochrane Collaboration tools (ROB-2) will assess the bias risk. Available data will be used to calculate effect sizes. Heterogeneity between studies will be evaluated with I2. The trial sequential analysis will be used to eliminate false-positive results. The certainty of the evidence will be assessed using Grading of Recommendations, Assessment, Development and Evaluation criteria.
ETHICS AND DISSEMINATION: This systematic review and meta-analysis was deemed exempt from ethics review. Results will be disseminated through publication in peer-reviewed journals and research conferences.
PROSPERO REGISTRATION NUMBER: CRD42023464509.
Patients receive vemurafenib PO BID for 6 weeks and cobimetinib PO QD for 3 weeks, followed by 1 week off, and then continuing for 2 weeks. Patients then receive iodine 131 PO followed by 3 additional days of vemurafenib PO BID and cobimetinib PO QD. Patients receive thyrogen IM daily for 2 days followed by I-123 diagnostic scan during screening and on study. Patients also undergo MRI during screening, PET scan or CT scan and blood sample collection throughout the study and ultrasound imaging and I-131 whole body scan during follow up.
Physiotherapist-supervised Telerehabilitation as home exercise in Groups. Participants in the intervention group receive supervised Telerehabilitation by an experienced physiotherapist two days a week during four weeks. A computer and a camera will be installed where the exercise should take place. It will make it possible for the physiotherapist to see how the participants follow the exercise program and for the participants to follow the physiotherapist instructions on the screen. The participants will be instructed in the use of computer and receive a written guide. After four weeks the participants will on their own continue the Otago exercise Program for another 4 weeks by video sessions and still together in their already established groups. Otago Exercise Program consist of a walking plan, balance exercises, and a set of leg muscle strengthening exercises all progressing in degree of difficulty.
PURPOSE: A composition containing Myristicae semen extract is provided to effectively treat dysporia caused by stress and to use in a pharmaceutical composition and health food. CONSTITUTION: A pharmaceutical composition for preventing and treating irritable bowel syndrome contains Myristicae Semen extract as an active ingredient. The extract is obtained using water, low alcohol of 1-4 carbon atoms, non-polar solvent or mixture solvent thereof. The non-polar solvent is dichloromethane, chloroform, diethyl ether, ethyl acetate, hexane or supercritical fluid. The Myristicae Semen extract is extracted through stir extraction, hot water extraction, enfleurage extraction, reflux extraction, ultrasonic wave extraction or supercritical extraction. The composition is formulated for oral or parenteral administration. A health food for preventing and treating irritable bowel syndrome contains Myristicae Semen extract as an active ingredient. The food is used in the form of powder, granule, tablet, capsule, or beverage.
INTRODUCTION: The aim of this study was to evaluate whether a forensic odontologist working remotely could accurately undertake forensic dental identifications using videos produced by non-dental forensic staff operating an intra-oral video camera (IOVC). The study's aims were to assess the accuracy and time taken to perform remote forensic dental identifications in this manner.
MATERIALS AND METHODS: Eight cadavers from the Centre for Anatomy and Human Identification (CAHID), University of Dundee, UK, were examined by a forensic odontologist via a traditional dental examination. Their dental condition was recorded to serve as ante-mortem records for this study. Videos of each dentition were produced using an IOVC operated by a medical student. Post-mortem records were produced for each dentition from the videos by a remote second forensic odontologist who was not present at the traditional dental examination. The ante-mortem and post-mortem records were then compared, and identification was classified as positively established, possible or excluded.
RESULTS: Established identifications were positively made in all eight cases although there were some non-critical inconsistencies between ante-mortem and post-mortem records. Before the second opinion, 85.6% of the teeth per study subject were charted consistently. After the second opinion, the percentage of consistency increased to 97.2%. Each video on average was about 4.13 minutes in duration and the average time taken to interpret and chart the post-mortem dental examination at the first attempt was 11.63 minutes. The time taken to chart from the videos was greater than is typical of a traditional dental examination.
CONCLUSION: This pilot study supports the feasibility of undertaking remote dental identification. This novel "tele-dental virtopsy" approach could be a viable alternative to a traditional post-mortem dental examination, in situations where access to forensic dental services is difficult or limited due to geographical, logistical, safety, and/or political reasons.
The invention discloses a TRPA1 antibody, a method for preparing the same and application thereof, wherein the TRPA1 antibody comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 with amino acid sequences shown as SEQ ID NO. 56-58 respectively; and/or the light chain variable region comprises the amino acid sequences shown as SEQ ID NO. 59, SEQ ID NO. 9 and SEQ ID NO. 10 as LCDR1, LCDR2 and LCDR3 respectively. The TRPA1 antibody provided by the invention has relatively high affinity to TRPA1, and the screened TRPA1 antibody has obvious inhibition effect on AITC activated TRPA1 channel, and the IC50 is lower than 1.54 mu M and can reach 0.56 mu M at the lowest.
The present invention provides an oral preparation product for drug abstinence. The oral preparation product of the present invention is prepared from raw material medicine of 200 to 400 portions of Chinese milkwort herb, 150 to 255 portions of honeysuckle flower, 60 to 90 portions of scutellaria, 70 to 100 portions of cape jasmine fruit, 100 to 150 portions of red sage root, 80 to 120 portions of angelica, 120 to 180 portions of astragalus root, 35 to 55 portions of ginseng, 35 to 55 portions of deglued antler, 60 to 100 portions of prepared rehmannia root, 100 to 150 portions of white paeony root, 60 to 100 portions of tortoise shell and 40 to 60 portions of hemlock parsley by weight. Clinical observation prove that when a drug abstinence cigarette preparation of the present invention is used for detoxification treatment on opium addicts, all abstinence syndromes are obviously reduced in a second day after the treatment, the abstinence syndromes especially insomnia, addiction, anorexia, etc. have obvious reduction, the urine morphine rehabilitation time is between 2 and 4 days, and the present invention has no obvious toxic side effect, few adverse effect and no abnormal biochemical and laboratory examination result. Through the clinical observation, the drug abstinence cigarette preparation of the present invention has the characteristics of high detoxification speed, conspicuous curative effect, no obvious toxic side effect, etc. The medical composition of the present invention does not comprise any drug ingredient, and has no addiction.
### Teratogenic Effects 

Pregnancy Category C

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol should be given to a pregnant woman only if clearly needed.

Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS).
AIMS: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors significantly reduce the risk for hospitalizations for heart failure (HF) in patients with diabetes, and HF; findings in patients with chronic kidney disease (CKD) are not uniform. We aimed to perform a meta-analysis exploring the effect of SGLT-2 inhibitors on HF events in patients with CKD and across subgroups defined by baseline kidney function.
METHODS AND RESULTS: A systematic search in major electronic databases was performed. Randomized controlled trials (RCTs) providing data on the effect of SGLT-2 inhibitors on the primary outcome, time to hospitalization or urgent visit for worsening HF in patients with prevalent CKD at baseline or across subgroups stratified by baseline estimated glomerular-filtration-rate (eGFR) were included. Twelve studies (n = 89,191 participants) were included in the meta-analysis. In patients with CKD, treatment with SGLT-2 inhibitors reduced the risk for HF events by 32% compared to placebo [hazard ratio (HR) 0.68; 95% confidence interval (CI) 0.63-0.73]. Reduction in HF events with SGLT-2 inhibitors was more prominent in patients with eGFR <60 ml/min/1.73 m2 (HR 0.68; 95% CI 0.62-0.74) than in those with eGFR ≥60 ml/min/1.73 m2 (HR 0.76; 95% CI 0.69-0.83). Subgroup analysis according to type of SGLT-2 inhibitor showed a consistent treatment effect across all studied agents (p-subgroup-analysis = 0.44). Sensitivity analysis including data from studies including only diabetic patients showed an even more pronounced effect in eGFR subgroup <60 ml/min/1.73 m2 (HR 0.62; 95% CI 0.54-0.70).
CONCLUSION: Treatment with SGLT-2 inhibitors led to a significant reduction in HF events in patients with CKD. Such findings may change the landscape of prevention of HF events in patients with advanced CKD. PROSPERO Registration number CRD42022382857.
Headache, blurring of vision, confusion, drowsiness, syncope, fatigue, edema, thrombophlebitis, hematemesis, diarrhea, and pain. These did not appear to be dose related and were not unequivocally drug related. They may have been due to the primary or metastatic disease processes. Malaise and asthenia have been reported as part of postmarketing surveillance. Bladder fibrosis/contraction has been reported with intravesical administration (see PRECAUTIONS). 

To report SUSPECTED ADVERSE REACTIONS, contact RK Pharma Inc. at 1-844-757-4276 (1-844-4-RKPHARM). or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.